STRO (Sutro Biopharma) Price-to-Funds-From-Operations: (As of Aug. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STRO Sutro Biopharma Inc STRO
45 GF Score
Price $20.46
GF Value $5.50
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Sutro Biopharma Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.

STRO
45GF Score
Sutro Biopharma Inc STRO
Price-to-Funds-From-Operations is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sutro Biopharma (STRO) Overvalued in 2026?

Based on GuruFocus' analysis, Sutro Biopharma stock appears to be overvalued. The current stock price of $20.46 is trading 272% above its estimated GF Value™ of $5.50. GuruFocus considers Sutro Biopharma to be Significantly Overvalued.

Key valuation signals for STRO:

  • Price-to-Funds-From-Operations:
  • GF Value™: $5.50 vs. price of $20.46 (272% above fair value)
  • GF Score™: 45/100 with 4 warning signs

No single metric tells the full story. See the STRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sutro Biopharma Business Description

Other Exchanges S090:Germany
Address 111 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
45GF Score

Get the complete analysis for STRO

Price-to-Funds-From-Operations is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.46
Price
$5.50
GF Value